Companies › OBI Pharma
4 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| adagloxad simolenin (OBI-822)/OBI-821 anti-Globo H glycolipid vaccine with immune adjuvant | – | Phase 3 | Triple Negative Breast Cancer | Dec 2027 |
| OBI-833/OBI-821 Globo H-targeting immunotherapy (cancer vaccine) | GLOBOH | Phase 2 | Non-small Cell Lung Cancer | – |
| OBI-992 Anti-TROP2 antibody-drug conjugate with exatecan payload | TROP2 | Phase 1 | Advanced Solid Tumor | Jun 2027 |
| OBI-902 antibody-drug conjugate | – | Phase 1 | Advanced Solid Tumor | Feb 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05442060 | OBI-833/OBI-821 | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2025 |
| NCT06480240 | OBI-992 | Phase 1 | Advanced Solid Tumor | Oncology | Jun 2027 |
| NCT03562637 | adagloxad simolenin (OBI-822)/OBI-821 | Phase 3 | Triple Negative Breast Cancer | Oncology | Dec 2027 |
| NCT07124117 | OBI-902 | Phase 1 | Advanced Solid Tumor | Oncology | Feb 2029 |
GSK Sichuan Baili Pharmaceutical Astellas Beijing Biotech Akeso MacroGenics Mabwell (Shanghai) Bioscience Bio-Thera Solutions LigaChem Biosciences
Lantheus Medical Imaging Shenzhen TargetRx InxMed (Shanghai) PharmaMar Stemline Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.